What's new? Log in Free sign up

Alnylam Pharmaceuticals (ALNY) News and press releases

Company Profile

News

From Benzinga Pro

SVB Leerink Maintains Market Perform on Alnylam Pharmaceuticals, Lowers Price Target to $143

News, Price Target, Analyst Ratings

SVB Leerink analyst Mani Foroohar maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Market Perform and lowers the price target from $144 to $143.

Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Canaccord Genuity Initiates Coverage On Alnylam Pharmaceuticals with Buy Rating, Announces Price Target of $310

News, Price Target, Initiation, Analyst Ratings

Canaccord Genuity analyst Whitney Ijem initiates coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy rating and announces Price Target of $310.

Alnylam Submits Clinical Trial Authorization Application For ALN-KHK, An Investigational RNAi Therapeutic For The Treatment Of Type 2 Diabetes

Biotech, News, FDA, General

–Company Expects to Initiate a Phase 1/2 Study for ALN-KHK in Early 2023, with Initial Results Expected in Late 2023 – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi (RNA

Meta To Rally Over 29%? Here Are 10 Other Price Target Changes For Friday

News, Price Target, Markets, Analyst Ratings, Trading Ideas

Piper Sandler Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $253

News, Price Target, Analyst Ratings

Piper Sandler analyst Edward Tenthoff maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and raises the price target from $226 to $253.

Alnylam Submits Supplemental New Drug Application To U.S. FDA For ONPATTRO For The Treatment Of The Cardiomyopathy Of ATTR Amyloidosis

Biotech, News, FDA, General

– sNDA Submission is Based on Findings from the APOLLO-B Phase 3 Study That Showed Patisiran Demonstrated Significant Improvement on Functional Capacity, Health Status and Quality of Life Compared to Placebo at

Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims

Biotech, Large Cap, News, Penny Stocks, Health Care, Small Cap, Legal, Pre-Market Outlook, General

Press releases

From Benzinga Pro

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial Results

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2022 on Thursday, February

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates

– Achieved Full Year 2022 Preliminary Global Net Product Revenues of $894 Million for ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®, Representing 35% Annual Growth (43% Using Constant Exchange

Alnylam Announces Updates to its Board of Directors

– Appoints Carolyn Bertozzi, Ph.D., Nobel Laureate and Leading Voice for Chemical Biology, Emerging Technology, and Life Sciences Companies – – Michael W. Bonney Steps Down as Executive Chair and Continues on Board as

Alnylam to Webcast Presentation at 41st Annual J.P. Morgan Healthcare Conference

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 41st Annual J.P. Morgan

Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day

− Product and Pipeline Goals Detail Execution across Four Commercial Brands, Including One Potential Label Expansion, and Ten Clinical Data Readouts From Proprietary and Partner Programs – − Pipeline Programs and

Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

– sNDA Submission is Based on Findings from the APOLLO-B Phase 3 Study That Showed Patisiran Demonstrated Significant Improvement on Functional Capacity, Health Status and Quality of Life Compared to Placebo at Month 12

Alnylam to Webcast Virtual R&D Day

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company's website,

Alnylam Ranks #1 on Boston Globe's Top Places to Work List for 2022

- Recognition Marks Alnylam's Eighth Year in a Row on this Prestigious List, and the Second Consecutive Year Ranking #1 - Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced